Sentinel surveillance of invasive candidiasis in Spain: Epidemiology and antifungal susceptibility

Diagnostic Microbiology and Infectious Disease

Volumn 81, Issue 1, 2015, Pages 34-40

  Nieto, M C ^a   Telleria O ^a   Cisterna, R ^a  

^a HOSPITAL DE BASURTO   (Spain)

Author keywords

Antifungals; Candidemia; Echinocandins; Epidemiology; Invasive candidiasis; Susceptibility

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CHILD; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; NEWBORN; NONHUMAN; PROSPECTIVE STUDY; RISK FACTOR; SENTINEL SURVEILLANCE; SPAIN; VERY ELDERLY; CANDIDA; CANDIDIASIS, INVASIVE; CLINICAL TRIAL; DRUG EFFECTS; HOSPITAL; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS, INVASIVE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, FUNGAL; FEMALE; HOSPITALS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; SENTINEL SURVEILLANCE; SPAIN; YOUNG ADULT;

EID: 84916215615     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.05.021     Document Type: Article

References (43)

1. Almirante B., Rodríguez D., Park B.J., Cuenca- Estrella M., Planes A.M., Almela M., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population- based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835.
2. Alonso-Valle H., Ancha O., García-Palomo J.D., Fariñas-Alavarez C., Fernández-Mazarrasa C., Fariñas M.C. Candidemia at a tertiary care hospital: epidemiology and factors influencing mortality. Eur J Clin Microbiol Infect Dis 2003, 22(4):254-257.
3. Beyda N.D., Chuang S.H., Alam M.J., Shah D.N., Ng T.M., McCaskey L., et al. Treatment of Candida famata bloodstream infections: case series and review of the literature. J Antimicrob Chemother 2013, 68:438-443.
4. Cervera C. Candidemia y candidiasis invasora en el adulto. Formas clínicas y tratamiento. Enferm Infecc Microbiol Clin 2012, 30(8):483-491.
5. Cisterna R., Ezpeleta G., Telleria O., Guinea J., Regueiro B., Garcia-Rodríguez J., et al. Nationwide Sentinel Surveillance of Bloodstream Candida Infections in 40 Tertiary Care Hospitals in Spain. J Clin Microbiol 2010, 48(11):4200-4206.
6. CLSI Interpretive Criteria for Identification of Bacteria and Fungi by DNA Target Sequencing; Approved Guideline. CLSI document MM18-A 2008, Clinical and Laboratory Standards Institute, Wayne, PA.
7. CLSI Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast; Third Informational Supplement. CLSI document M27- S3 2008, Clinical and Laboratory Standards Institute, Wayne, PA.
8. Colombo A.L., Perfect J., DiNubile M., Bartizal K., Motyl M., Hicks P., et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003, 22:470-474.
9. Concia E., Azzini A.M., Conti M. Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients. Drugs 2009, 69(1):5-14.
10. Cornely O.A., Bassetti M., Calandra T., Garbino J., Kullberg B.J., Lortholary O., et al. M.ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012, 18(7):19-37.
11. De Bedout C., Gomez B.L. Candida y candidiasis invasora: un reto continuo para su diagnóstico temprano. Infectio 2010, 14(2):159-171.
12. Deresinski S.C., Stevens D.A. Caspofungin. Clin Infect Dis 2003, 36:1445-1457.
13. Forrest G.N., Weekes E., Johnson J.K. Increasing in cadence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008, 56(2):126-129.
14. Garcia-Effron G., Canton E., Pemán J., Dilger A., Romá E., Perlin D.S. Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital. J Antimicrob Chemother 2012, 67(11):2739-2748.
15. Gómez J., García-Vázquez E., Espinosa C., Ruiz J., Canteras M., Hernández-Torres A., et al. Nosocomial candidemia at a general hospital: prognostic factors and impact of early empiric treatment on outcome (2002-2005). Med Clin (Barc) 2010, 134(1):1-5.
16. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., et al. Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry. Clin Infect Dis 2009, 48:1695-1703.
17. Kartsonis N., Killar J., Mixson L., Hoe C.M., Sable C., Bartizal K., et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother 2005, 49(9):3616-3623.
18. Kett D.H., Shorr A.F., Reboli A.C., Reisman A.L., Biswas P., Schlamm H.T. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive Candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis. Crit Care 2011, 15(5):R253.
19. Kullberg B.J., Verweij P.E., Akova M., Arendrup M.C., Bille J., Calandra T., et al. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect 2011, 17(Suppl 5):1-12.
20. Levy I., Rubin L.G., Vasishtha S., Tucci V., Sood S.K. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 1998, 26:1086-1088.
21. Lionakis M.S., Netea M.G. Candida and Host Determinants of Susceptibility to Invasive Candidiasis. PLoS Pathog 2013, 9(1):e1003079. 10.1371/journal.ppat.1003079.
22. Marr K.A., Seidel K., White T.C., Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000, 181:309-316.
23. Mayr A., Aigner M., Lass-Flörl C. Anidulafungin for the treatment of invasive candidiasis. Clin Microbiol Infect 2011, 17(1):1-12.
24. McCabe W.R., Jackson G.G. Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med 1962, 110:847-853.
25. Messer S.A., Moet G.J., Kirvy J.T., Jones R.N. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY antimicrobial surveillance program (2006 to 2007). J Clin Microbiol 2009, 47:1942-1946.
26. Moore C.B., Oakley K.L., Denning D.W. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect 2001, 7(1):11-16.
27. Moudgal V., Little T., Boikov D., Vazquez J.A. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005, 49(2):767-769.
28. Nucci M., Queiroz-Telles F., Tobón A.M., Restrepo A., Colombo A.L. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010, 51(5):561-570.
29. Nucci M., Queiroz-Telles F., Alvarado-Matute T., Tiraboschi I.N., Cortes J., et al. Epidemiology of Candidemia in Latin America: A Laboratory-Based Survey. PLoS ONE 2013, 8(3):e59373. 10.1371/journal.pone.0059373.
30. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 2003, 47(10):3149-3154.
31. Pappas P.G., Rex J.H., Lee J., Hamill R.J., Larsen R.A., Powderly W., et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643.
32. Pemán J., Cantón E., Camarena J.J., Alcoba J., Echeverria J., Navarro D., et al. Variación de la epidemiología de las fungemias y de la sensibilidad al fluconazol de los aislamientos de hemocultivos en los últimos 10 años en España: resultados del estudio FUNGEMYCA. Rev Iberoam Micol 2011, 28(2):91-99.
33. Pfaller M.A. Anidulafungin: an echinocandin antifungal. Expert Opin Investig Drugs 2004, 13:1183-1197.
34. Pfaller M.A., Diekema D.J. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin Microbiol Rev 2007, 20(1):33-163.
35. Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010, 36(1):1-53.
36. Pfaller M.A., Boyken I., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46(1):150-156.
37. Quindós G. Nosocomial candidemias and invasive candidiasis. Med Clin 2010, 134(1):17-19.
38. Ruiz-Camps I., Cuenca-Estrella M. Antifúngicos para uso sistémico. Enferm Infecc Microbiol Clin 2009, 27(6):353-362.
39. Tortorano A.M., Peman J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
40. Viscoli C., Girmenia C., Marinus A., Collette L., Martino P., Vandercam B., et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999, 28:1071-1079.
41. Wingard J.R. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995, 20:115-125.
42. Wingard J.R., Merz W.G., Rinaldi M.G., Johnson T.R., Karp J.E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991, 325:1274-1277.
43. Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41:1232-1239.